Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TV-44749 subcutaneous olanzapine vs oral olanzapine in schizophrenia
NCT06315283Phase 1Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of TEV-749 in schizophrenia (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Area Under the Curve. Started Mar 2024; status: completed.
02
Drugs
TEV-749
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06315283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06315283.